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Abstract
Modulatory cytokines such as IL-4 and IL-10 looked promising
biologicals, but suffered from poor exposure at the inflamed joints
when administered via the patient-friendly subcutaneous route.
Immunocytokines have now been engineered with tissue targeting
potential and are a possible solution to this problem, although
challenges still exist. Local inflammatory processes cause destruc-
tion of extracellular matrix (ECM) components, leading to neo-
eptitopes, and/or elicit the synthesis of new ECM components.
This makes ECM elements interesting targets for antibody-
mediated recognition and retention, to achieve higher levels of
immunocytokines at the site of therapeutic interference. The study
presented by Schwager and colleagues shows that targeted
delivery of IL-10 is more efficacious in experimental arthritis.
Clinical studies are warranted to show whether this strategy works
for all rheumatoid arthritis patients or is better for subgroups with a
defined ECM phenotype. In principle, the scFv-targeting system is
plastic enough to allow for personalized strategies.
Immunocytokines
The successful introduction of biologicals such as neutralizing
anti-TNF-antibodies in the treatment of rheumatoid arthritis has
paved the way for using immunocytokines in non-lethal
diseases. The study of Kathrin Schwager and colleagues [1] in
a recent issue of Arthritis Research & Therapy reports
impressive preclinical results using F8-IL-10 (DEKAVIL), a fully
human fusion protein of the single-chain Fv (scFv) antibody
F8, which specifically recognizes the extra-domain A (EDA) of
fibronectin, with the anti-inflammatory cytokine IL-10. They
showed the accumulation of this fusion protein at the site of
inflammation, good therapeutic efficacy and a safety profile
that provides the basis for the first clinical trial of antibody-
based pharmacodelivery of DEKAVIL in rheumatoid arthritis
(RA) patients
In general, immunocytokines are scFv fragments of a mono-
clonal antibody directed against a specific target fused to a
cytokine, thus retaining the functions of both the antibody and
the cytokine. In cancer, the use of single-chain antibody
fragments for targeting and in vivo imaging of tumors is a new
weapon in the oncologist’s armamentarium [2]. These scFvs
show good tumor targeting and biodistribution properties
with a tumor-to-background ratio of more than 10% ID/g.
Extracellular matrix components for retention
of immunocytokines
The therapeutic potential of recombinant cytokines is often
limited by severe toxicities due to the high dosages needed
as cytokines often have poor pharmacokinetics and dynamics.
A straightforward strategy is the fusion of cytokines with the
Fc tail of antibodies or liposomal encapsulation to increase
their half-life in the circulation, although this will not improve
the local accumulation [3,4]. Schwager and colleagues [1]
showed that cytokines can be targeted to the site of interest
by using scFv antibody fragments recognizing extracellular
matrix (ECM) components present in the joint. The first
question they addressed is which ECM protein is the best
targetable candidate in the inflamed joint. Their approach was
a side-by-side comparison of immunohistochemical staining
of synovial tissue of several antibodies directed against
different ECM antigens, and identified EDA, a splice variant of
fibronectin, as the best candidate. They showed a therapeutic
effect of F8-IL-10 that was better than an IL-10 fusion protein
directed against an irrelevant protein antigen.
Concomitant neutralization of signaling?
Unfortunately, they did not include in their studies the
therapeutic impact of the targeting antibody alone, without
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IL-10, or coupled to an inactive protein. It is now well
accepted that EDA is an endogenous Toll-like receptor 4
(TLR4) ligand [5], and the F8 scFv antibody fragment
possibly interferes with EDA-induced TLR4 signaling by
blocking or steric hindrance. We recently demonstrated an
important role for TLR4 in experimental arthritis. Blocking
TLR4 using Bartonella lipopolysaccharide, a naturally
occurring TLR4 antagonist, clearly ameliorates murine
collagen-induced arthritis [6]. This potential double hit may
add another layer of activity to the immunocytokines. The
possibilities are unlimited as recombinant antibody fragments
can be engineered to assemble into stable multimeric
oligomers of high binding avidity and specificity to a wide
range of target antigens and haptens [7]. Multi-specific Fv
modules can be designed as cross-linking reagents for local
accumulation of cytokine action through attachment to the
ECM and by targeting carrier cells or proteins for trafficking
to the joint. Furthermore, it is possible to select human svFc
monoclonal autoantibodies for ECM proteins from B-cell
phage-display libraries derived from RA patients that are
more specific (recognizing RA-specific neo-epitopes as
citrullinated antigens) and have higher affinities [8]. As well as
the ECM, other proteins that are extremely upregulated and
pro-arthritic in the inflamed joint (for example, S100 alarmins)
are candidate targets for scFv antibody-based immunocyto-
kines [9].
Local delivery versus local accumulation?
Intra-articular therapy is attractive in RA patients to enhance
efficacy of a drug and reduce side-effects associated with
systemic immunosuppression. Rheumatologists are familiar
with local injections - for example, to extinguish the inflamma-
tion in affected joints with corticosteroids. Results from local
delivery of anti-TNF biologicals are encouraging, and although
a plausible form of therapy, larger studies are warranted to
address the safety issues associated with repeated and
prolonged antibody delivery in the joint [10]. The gene-therapy
field has acknowledged this strategy and used recombinant
vectors to transduce the synovium and produce biologicals
locally. However, even using local gene delivery, effects on
ipsilateral and contralateral joints were reported, although it
remains debatable whether this reflected spill-over of
biologicals to the system [11]. Combining the best of both
strategies - local synthesis and retention using scFv antibodies
against ECM components - can be envisioned.
Perspective
The successful introduction of immunocytokines as a magic
bullet in the treatment of RA will depend on the spontaneous
generation of autoantibodies against the svFc part of the
molecule. The presence of anti-idiotypic antibodies has been
identified in sera of RA patients, and these antibodies may
impair the accumulation of immunocytokines, neutralize the
cytokine activity and prohibit repeated injection. So far, auto-
antibodies against fully humanized anti-TNF antibodies have
not been a major problem and we are hopeful that
immunocytokines will become a therapeutic reality in RA
patients in the near future.
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